Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced the appointment of Michael Halstead as its new chief executive officer, effective immediately. The move comes as the clinical-stage company advances its lead candidate, HLP003, through Phase 3 development and positions itself for potential commercialization. Halstead brings 25 years of biopharmaceutical leadership experience, most recently serving as president of Intra-Cellular Therapies, where he oversaw the development and commercialization of CAPLYTA(R), supported pipeline expansion, and helped lead the company's $14.6 billion acquisition by Johnson & Johnson in 2025. This leadership change is significant for Helus Pharma and its stakeholders, as the company navigates a critical phase in its development pipeline.
The appointment coincides with major milestones in the company's clinical programs. Enrollment is complete in the Phase 3 APPROACH trial for HLP003, with topline data expected in Q4 2026. Additionally, enrollment continues in the EMBRACE pivotal study, and the company is also advancing HLP004, a candidate for generalized anxiety disorder, currently in Phase 2. These developments underscore the company's momentum in addressing mental health conditions, an area of substantial unmet medical need. The new CEO's experience in commercializing psychiatric treatments is likely to be instrumental in guiding Helus Pharma through its next stages of growth.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to developing proprietary novel serotonergic agonists (NSAs) designed to activate serotonin pathways and promote neuroplasticity. These synthetic molecules aim to provide durable improvements in mental health, targeting conditions such as depression and anxiety. HLP003, the company's lead candidate, is being developed as an adjunctive treatment for major depressive disorder and has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. The company operates in Canada, the United States, the United Kingdom, and Ireland.
The appointment of a seasoned executive like Halstead is a strong signal of Helus Pharma's commitment to advancing its pipeline and preparing for potential market entry. His track record in bringing psychiatric medications to market and managing successful acquisitions will be valuable as the company awaits Phase 3 data and continues its pivotal studies. For investors and industry observers, this leadership change could influence confidence in the company's strategic direction and its ability to execute on its development goals.
The news of Halstead's appointment and the progress of the clinical trials were disseminated by NetworkNewsWire, a specialized communications platform that focuses on financial news and content distribution. The full press release can be found at https://nnw.fm/wCjAp. For the latest updates on Helus Pharma, visit the company's newsroom at https://nnw.fm/HELP.
This leadership transition comes at a pivotal time for Helus Pharma, as it aims to address the large unmet need for effective treatments for depression and anxiety. With the Phase 3 APPROACH trial fully enrolled and topline data anticipated in the coming years, the company is poised to make significant strides in the mental health treatment landscape. The appointment of Michael Halstead, with his extensive experience in psychiatric drug commercialization, may prove to be a strategic move as the company prepares for potential regulatory submissions and market entry. As the company advances its pipeline, the industry will be watching closely to see how these developments unfold.
